News | Patient Positioning Radiation Therapy | September 22, 2017

Augmenix to Release New SpaceOAR Hydrogel Clinical Data at ASTRO 2017

Series of poster presentations, late-breakers and panel discussions will examine clinical and quality of life benefits of novel absorbable hydrogel spacing technology for prostate cancer treatment

Augmenix to Release New SpaceOAR Hydrogel Clinical Data at ASTRO 2017

September 22, 2017 — Augmenix Inc. announced a preview of clinical data that will be presented at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO 2017), Sept. 24-27 in San Diego. The presentations will provide new insights on the clinical and quality of life benefits of the company’s novel absorbable hydrogel spacing technology in providing protection during radiation therapy.

SpaceOAR hydrogel, Augmenix’s lead product, is U.S. Food and Drug Administration (FDA)-cleared and is designed to protect the rectum in men undergoing radiation therapy for prostate cancer.

Most notably at ASTRO 2017, results from the first prospective study evaluating the efficacy of SpaceOAR hydrogel in patients undergoing high-dose stereotactic body radiation therapy (SBRT) for prostate cancer will be presented as a late-breaking clinical trial on Tuesday, Sept. 26. Additionally, the first five-year quality of life data results in prostate cancer patients treated with SpaceOAR hydrogel will unveiled the same day in an oral presentation, demonstrating significant bowel and sexual function benefits. A didactic industry-sponsored panel discussion on the present and future role of hydrogel spacing in the treatment of prostate cancer, led by renowned radiation oncologists from around the world, will occur on Monday, Sept. 25.

Following is a detailed schedule of the company’s events in chronological order (times are U.S. Pacific Daylight Time):

Sunday, September 24

The following poster presentations will take place from 1:15 p.m. – 2:45 p.m. in the Poster Hall:

  • Poster Presentation (No : 2559): Dosimetry for Organs at Risk With and Without Use of Perirectal Hydrogel Spacer in Prostate Cancer Patients Treated With SBRT
    • Presented by: Daniel B. Fried, M.D., Ph.D., MPH
  • Poster Presentation (No : 2572): A Pilot Study – The Role of Radio-Opaque Hydrogel Tissue Marker in the Treatment of Postprostatectomy Intensity Modulated Radiation Therapy
    • Presented by Huong Ho, DO
  • Poster Presentation (No : 3383): Updated Retrospective Dose Volume Histogram Analysis of High Dose Rate Prostate Brachytherapy Patients With Hydrogel Spacer Implantation
    • Presented by Sean Cavanaugh, M.D.

 

Monday, September 25

  • Industry-Expert Theatre: Present and Future Role of Hydrogel Spacing in the Treatment of Prostate Cancer – 3 & 5 Year QOL Evidence and Stereotactic Body Radiation Therapy (SBRT) Experience
    • Time/Location: 12:30 p.m. – 1:30 p.m. Exhibit Hall – Theatre 1
    • Speakers: Robert Timmerman, M.D., professor of radiation oncology and neurology at the University of Texas Southwestern Medical Center in Dallas; Michael Zelefsky, M.D., professor of radiation oncology, vice-chair of the Department of Radiology and chief of the Brachytherapy Service at Memorial Sloan-Kettering Cancer Center in New York City; Daniel Hamstra, M.D., Ph.D., clinical director and professor at William Beaumont Oakland University Medical School, Department of Radiation Oncology, Beaumont Health, Dearborn, Mich.; and Prof. Dr. Michael Pinkawa, director of the Department of Radiation Oncology, MediClin Robert Janker Klinik in Bonn, Germany.
    • Moderator: Rodney Ellis, M.D., vice chair for clinical affairs at the University Hospitals Cleveland Medical Center and associate professor, radiation oncology at Case Western Reserve University in Cleveland.
  • Poster Presentation (No : 3613): The Rectal Dosimetric Effects of Perirectal Hydrogel Spacers in Men Undergoing Prostate Stereotactic Body Radiation Therapy (SBRT)
    • Time/Location: 4:15 p.m. – 5:45 p.m. Poster Hall
    • Presenter: Shaan Kataria, M.D.

Tuesday, September 26

  • Late-Breaking Abstracts Special Session (SS 22): Multi-Institutional Phase 2 Trial of High-Dose Stereotactic Body Radiation Therapy with Temporary Hydrogel Spacer for Low- and Intermediate-Risk Prostate Cancer
    • Time/Location: 7:45 a.m. – 9 a.m. Room 5A
    • Presenter: Michael Folkert, M.D.
  • ePoster Presentation (No: 1083): Quality of Life after Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: Five Year Results
    • Time/Location: 1:12 p.m. Room 5B
    • Presenter: Michael Pinkawa, M.D., Ph.D.
  • Poster Presentation (No : 2869): Biodegradable Hydrogel Spacer Injection for Contralateral Submandibular Gland Sparing in Radiation Therapy for Head and Neck Cancers
    • Time/Location: 2:45 p.m. – 4:15 p.m. Poster Hall
    • Presenter: Avani Rao, M.D.
  • Poster Presentation (No : 2435): Novel Use of a Hydrogel Spacer to Separate the Head of the Pancreas and Duodenum for Radiation Therapy for Pancreatic Cancer
    • Time/Location: 4:45 p.m. – 6:15 p.m. Poster Hall
    • Presenter: Avani Rao, M.D.

Read "Augmenix Announces Positive Three-Year Long-Term Data for SpaceOAR Hydrogel Spacer"

For more information: www.augmenix.com

Related Content

Mirada Medical Releases DLCExpert for Radiotherapy Treatment Planning
Technology | Treatment Planning | February 22, 2018
February 22, 2018 — U.K.-based medical imaging software provider Mirada Medical has released DLCExpert, the first com
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Mitchell Cancer Institute Selects RayStation for TomoTherapy Planning
News | Treatment Planning | February 16, 2018
The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Ala., has selected RayStation as its...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
Patients Lack Information About Imaging Exams
News | Patient Engagement | February 14, 2018
Patients and their caregivers desire information about upcoming imaging examinations, but many are not getting it,...
Varian Acquires Mobius Medical Systems
News | Quality Assurance (QA) | February 06, 2018
February 6, 2018 – Varian announced it has acquired privately-held Mobius Medical Systems, a...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Microbubbles Make Breast Cancer More Susceptible to Radiation Therapy
News | Women's Health | February 01, 2018
February 1, 2018 – Injecting breast cancer with oxygen-filled microbubbles makes tumors three-times more sensitive to
Overlay Init